LONDON, Nov. 16, 2017 /PRNewswire/ --
Fore Pharma announced the results of its Epilepsy patients study in a new report 'Global Epilepsy Epidemiology and Patient Flow Analysis - 2017'.
Download the full report: https://www.reportbuyer.com/product/3895247The report provides insights into Epilepsy epidemiology, Epilepsy diagnosed patients, and Epilepsy treatment rate for top seven pharmaceutical markets. The study measures
key indicators such as prevalence of Epilepsy derived from epidemiological analysis, percentage of patients diagnosed with Epilepsy, and percentage of patients treated with a therapy. The study helps executives estimate Epilepsy market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions. The report provides estimates and forecasts of Epilepsy prevalence, Epilepsy diagnosis rate, and Epilepsy treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources. Key Features of the Report: - Epilepsy Patient Flow - Epilepsy Prevalence - Epilepsy Diagnosed Patients - Epilepsy Treated PatientsDownload the full report: https://www.reportbuyer.com/product/3895247 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/global-epilepsy-epidemiology-and-patient-flow-analysis---2017-300558367.html